Hepatocellular Carcinoma Archives

Patients with HCC who have advanced on sorafenib have poor prognosis and few additional treatment op

Sintilimab Plus IBI305 for Hepatitis B Virus-Positive Hepatocellular Carcinoma

By

August 12, 2021

The combination of sintilimab and IBI305 improved progression-free survival in patients with unresectable hepatocellular carcinoma.

It was determined that ICIs were less efficacious in Taiwanese patients with melanoma.

Gastrointestinal Cancer

Donafenib Bests Sorafenib in Chinese Patients With Advanced Hepatocellular Carcinoma

By

Sucharita Mistry, PhD

July 20, 2021

Overall survival was superior with donafenib.

Safety and Efficacy Sorafenib Treatment for Hepatocellular Carcinoma Among Age Groups

Gastrointestinal Cancer

Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma Showed Better Improvement in Patient-Reported Outcomes

By

Jessica Nye, PhD

June 29, 2021

Patient reported outcomes for quality of life, emotional and social functioning, and general disease symptoms were better with atezolizumab/bevacizumab compared with sorafenib monotherapy.

Gastrointestinal Cancer

SIRT Is More Cost-Effective Than Sorafenib in Locally Advanced HCC

By

Andrea S. Blevins Primeau, PhD, MBA

January 26, 2021

Investigators compared the cost-effectiveness of selective internal radiotherapy (SIRT) of that of sorafenib in the locally advanced hepatocellular carcinoma setting.

liver affected by cirrhosis and hepatitis

Gastrointestinal Cancer

Study Data Suggest Role for Lenvatinib in Unresectable HCC With Child-Pugh B Liver Function

By

Victoria Forster, PhD

January 19, 2021

Outcomes of lenvatinib-receiving patients who progressed to Child-Pugh B liver function within the first 8 weeks of treatment were compared with those of patients who maintained Child-Pugh A classification during the same time period.

Novel Kinase Inhibitor Shows Efficacy in Patients with Advanced HCC Tumors Overexpressing AFP

Gastrointestinal Cancer

Tivozanib and Durvalumab Doublet Regimen Is Well-Tolerated in HCC

By

Andrea S. Blevins Primeau, PhD, MBA

January 15, 2021

Combination tivozanib and durvalumab was found to be well-tolerated in patients with advanced, treatment-naïve hepatocellular carcinoma (HCC).

Publishers Alliance

Value of Follow-Up Chest Computed Tomography in the Surveillance of Patients with Hepatocellular Carcinoma

December 18, 2020

[Journal of Hepatocellular Carcinoma] Researchers at UT MD Anderson Cancer Center assessed the value of chest, abdominal, and pelvic CT in the surveillance of patients with HCC, and the potential drawbacks to the practice.

Publishers Alliance

Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

September 18, 2020

[Cancer Management and Research] Researchers present a simple classification method for assessing fatigue, which is proven to be a prognostic marker of TTP and OS in patients with HCC.

Liver Cancer

FDA Denies Accelerated Approval of Keytruda Plus Lenvima for Unresectable HCC

By

Brian Park, PharmD

July 14, 2020

In the CRL, the FDA stated that the data from KEYNOTE-524/Study 116 did not demonstrate a meaningful advantage over available therapies for unresectable or metastatic HCC.

Publishers Alliance

Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma

June 26, 2020

[Cancer Management and Research] Researchers sought to determine if apatinib-related hypertension was a predictor of drug efficacy in patients with advanced HCC.